ICL: Sales and adjusted EBITDA grew as portfolio resilience offset cost and market pressures

ICL Group reported Q3 sales up 3% YoY and adjusted EBITDA up 1%, with adjusted net income rising 2%. Segment results varied. The company reiterated its FY26 guidance, citing pricing and cost actions to offset market pressures.

Original reporting
Published Nov 11, 2026, 3:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ICL: Sales and adjusted EBITDA grew as portfolio resilience offset cost and market pressures — source image
Decision brief

The 30-second read

$ICLNeutralMed
01

Why it matters

The earnings release provides fresh data that could adjust short‑term pricing expectations for ICL.

02

Market read

First report of Q3 results; modest growth may lead to limited price movement.

03

What to watch

Potential impact of raw‑material and freight cost volatility on future earnings.

Relevance 7/10Novelty 7/10Timing: after-hours release

Background

ICL Group Ltd. released its Q3 2026 earnings via a SEC 6‑K filing, highlighting modest revenue and EBITDA growth.

Company-level read

Ticker impact

$ICLNeutralHigh confidence
Context

Q3 sales rose 3% YoY and adjusted EBITDA increased 1% as reported in ICL's SEC 6‑K filing.

Expected impact

potential modest move as market digests the modest growth and reaffirmed FY26 guidance

Evidence & confidence

Numbers are new and directly from the filing; impact likely limited to short‑term price adjustment.

Market effects

Provides a modest positive signal for the specialty chemicals sector.

May slightly influence Israeli and broader European chemical markets.

Limited global impact; primarily relevant to investors in ICL and peers.

Counterpoint

Growth is modest and may not justify a price rally; cost pressures could weigh on margins.

Key entities

  • ICL Group Ltd.

    Israeli chemicals producer listed on NYSE under ticker ICL.

Related articles

$ICLMedAI 8/10

ICL Group Ltd (ICL) Q3 2026 Earnings Call Highlights: Industrial Strength and Cost Cuts

ICL Group Ltd reported Q3 2026 earnings, with CEO Elad Aronson and CFO Assaf discussing market outlook, segment performance, and cost management. Key points include stable potash demand, rising phosphate fertilizer demand, and falling sulfur prices. Industrial products sales rose 18% YoY to $347M, with EBITDA up nearly 50%. Potash EBITDA declined 7% YoY due to higher costs. The company expects 2026 EBITDA to be within the $1.5B-$1.7B guidance range, with relief from sulfur costs in 2027.

$ICLMed

ICL Group Ltd Q3 2026 Earnings Call Summary

ICL Group Ltd reported Q3 2026 earnings, highlighting growth from strategic price increases and high-margin products. Key segments showed mixed results: Industrial Products benefited from bromine price increases, Phosphate Solutions saw resilience in specialty products, and Potash margins faced pressure. The company expects 2026 EBITDA of $1.5B-$1.7B and $150M EBITDA improvement in 2027 from cost-cutting.

$ICLMedAI 8/10

ICL Group Q3 Earnings Call Highlights

ICL Group reported Q3 average potash price at $370/ton, up 5% YoY. Phosphate Solutions sales were $589M, EBITDA $118M. Growing Solutions sales were $538M, EBITDA $44M. Sulfur costs rose 220% YoY, impacting Q4. ICL expects $150M EBITDA improvement by 2027. Company to reorganize segments in 2027. Maintained 2026 potash sales forecast of 4.5-4.7M metric tons. Paid $63M dividend in Q3.

$ICLHighAI 8/10

ICL Group (ICL) Q3 2026 Earnings Call Transcript

ICL Group reported Q3 2026 adjusted net income of $126M, up 2%, with EPS at $0.10. Operating cash flow was $256M, and free cash flow was $66M. Industrial Products sales rose 18% YoY, driven by higher bromine prices. Potash sales increased 4% YoY, but EBITDA fell 7% due to cost pressures. Phosphate Solutions sales were $589M with a 20% EBITDA margin, despite higher raw material costs. Growing Solutions sales were $538M with EBITDA of $44M, facing market challenges in Brazil.